TG Therapeutics, Inc.
TG Therapeutics, Inc. (TGTX) Stock Overview
Explore TG Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.9B
P/E Ratio
136.90
EPS (TTM)
$0.25
ROE
0.19%
TGTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of TG Therapeutics, Inc. (TGTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.07, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $40.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 136.90 and a market capitalization of 5.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.